Functional Investigations of p53 Acetylation Enabled by Heterobifunctional Molecules
Open accessThe DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Abstract
Post-translational modifications (PTMs) dynamically regulate the critical stress response and tumor suppressive functions of p53. Among these, acetylation events mediated by multiple acetyltransferases lead to differential target gene activation and subsequent cell fate. However, our understanding of these events is incomplete due to, in part, the inability to selectively and dynamically control p53 acetylation. We recently developed a heterobifunctional small molecule system, AceTAG, to direct the acetyltransferase p300/CBP for targeted protein acetylation in cells. Here, we expand AceTAG to leverage the acetyltransferase PCAF/GCN5 and apply these tools to investigate the functional consequences of targeted p53 acetylation in human cancer cells. We demonstrate that the recruitment of p300/CBP or PCAF/GCN5 to p53 results in distinct acetylation events and differentiated transcriptional activities. Further, we show that chemically induced acetylation of multiple hotspot p53 mutants results in increased stabilization and enhancement of transcriptional activity. Collectively, these studies demonstrate the utility of AceTAG for functional investigations of protein acetylation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“AceTACs recruiting GCN5 to p53 have resulted in different acetylation sites being edited and distinct transcriptional activation from p300 recruitment [51].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
COSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559 · cited 1×
“10,78 Other studies have proposed that p53 acetylation recruits transcription coactivators, such as p300/CBP to its target gene promoters, leading to acetylation of neighboring histones and transcription-related components.”
A model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
PUMA, a Novel Proapoptotic Gene, Is Induced by p53
Nakano, K., & Vousden, K. H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00214-3 · Cited by 2,315
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610
How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression
Aubrey, B. J., Kelly, G. L., Janic, A., Herold, M. J., & Strasser, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.169 · Cited by 1,395
The growing landscape of lysine acetylation links metabolism and cell signalling
Choudhary, C., Weinert, B. T., Nishida, Y., Verdin, E., & Mann, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3841 · Cited by 1,324
Cell cycle regulation: p53-p21-RB signaling
Engeland, K. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00988-z · Cited by 1,274
Post-translational modification of p53 in tumorigenesis
Bode, A. M., & Dong, Z. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1455 · Cited by 1,270
Radiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242
Functions and mechanisms of non-histone protein acetylation
Narita, T., Weinert, B. T., & Choudhary, C. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0081-3 · Cited by 1,232
Shaping the nuclear action of NF-κB
Chen, L.-F., & Greene, W. C. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1368 · Cited by 1,221
Self-citationDNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204
The dTAG system for immediate and target-specific protein degradation
Nabet, B., Roberts, J. M., Buckley, D. L., Paulk, J., Dastjerdi, S., Yang, A., Leggett, A. L., Erb, M. A., Lawlor, M. A., Souza, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0021-8 · Cited by 1,118
Self-citationCensus and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971 · cited 4×
“Interestingly, both AceTAG p300/CBP -1 and AceTAG PCAF/GCN5 -4 resulted in transcriptional repression of some genes, though none were identified as high-confidence p53 targets, 11 potentially the result of indirect repression pathways 11,74,75 (Group 6).”
InfluentialTP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes
Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884
Jin, Q., Yu, L., Wang, L., Zhang, Z., Kasper, L. H., Lee, J., Wang, C., Brindle, P. K., Dent, S. Y. R., & Ge, K. (2011) · The EMBO Journal · doi:10.1038/emboj.2010.318 · Cited by 877
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Lasko, L. M., Jakob, C. G., Edalji, R. P., Qiu, W., Montgomery, D., Digiammarino, E. L., Hansen, T. M., Risi, R. M., Frey, R., Manaves, V., et al. (2017) · Nature · doi:10.1038/nature24028 · Cited by 858
Acetylation Is Indispensable for p53 Activation
Tang, Y., Zhao, W., Chen, Y., Zhao, Y., & Gu, W. (2008) · Cell · doi:10.1016/j.cell.2008.03.025 · Cited by 838 · cited 3×
“…Though acetylation by both p300/CBP and PCAF/GCN5 is considered to regulate expression of the principal cell cycle inhibitor, CDKN1A (encoding p21), 16,44 other common cell cycle arrest-related p53 target genes, such as GADD45 15 and BTG2 , 8 are reported to be controlled primarily by p300/CBP.…”
Influentialp53 Sites Acetylated In Vitro by PCAF and p300 Are Acetylated In Vivo in Response to DNA Damage
Liu, L., Scolnick, D. M., Trievel, R. C., Zhang, H. B., Marmorstein, R., Halazonetis, T. D., & Berger, S. L. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1202 · Cited by 776
Acetylation of the p53 DNA-binding domain regulates apoptosis induction.
Sykes, S. M., Mellert, H. S., Holbert, M. A., Li, K., Marmorstein, R., Lane, W. S., & McMahon, S. B. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.026 · Cited by 752
Tip60-Dependent Acetylation of p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis
Tang, Y., Luo, J., Zhang, W., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.021 · Cited by 727
Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., & Berger, S. L. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00414-2 · Cited by 710
Suzuki, S., Tanaka, T., Poyurovsky, M. V., Nagano, H., Mayama, T., Ohkubo, S., Lokshin, M., Hosokawa, H., Nakayama, T., Suzuki, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002459107 · Cited by 705
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 697
Structural Biology of the Tumor Suppressor p53
Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 693
Protein Lysine Acetylation by p300/CBP
Dancy, B. M., & Cole, P. A. (2015) · Chemical Reviews · doi:10.1021/cr500452k · Cited by 609
Why are there hotspot mutations in the TP53 gene in human cancers?
Baugh, E. H., Ke, H., Levine, A. J., Bonneau, R. A., & Chan, C. S. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.180 · Cited by 607 · cited 1×
“…doxycycline-inducible p53 mut - FKBP12 F36 V -HA H1299 cell lines expressing three of the ten most frequent hotspot mutations in the TP53 gene, 87 including two structural mutants, V157F and Y220C, which induce p53 misfolding and destabilization, 88 − 91 and a DNA contact surface mutant,…”
p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2
Ito, A., Lai, C.-H., Zhao, X., Saito, S., Hamilton, M. H., Appella, E., & Yao, T.-P. (2001) · The EMBO Journal · doi:10.1093/emboj/20.6.1331 · Cited by 582
Acetylation of p53 inhibits its ubiquitination by Mdm2
Li, M., Luo, J., Brooks, C. L., & Gu, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200578200 · Cited by 503
BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program
Ren, D., Tu, H.-C., Kim, H., Wang, G. X., Bean, G. R., Takeuchi, O., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J.-D., & Cheng, E. H.-Y. (2010) · Science · doi:10.1126/science.1190217 · Cited by 473
Acetylation Is Crucial for p53-Mediated Ferroptosis and Tumor Suppression
Wang, S.-J., Li, D., Ou, Y., Jiang, L., Chen, Y., Zhao, Y., & Gu, W. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.022 · Cited by 462
Mechanisms of transcriptional regulation by p53
Sullivan, K. D., Galbraith, M. D., Andrysik, Z., & Espinosa, J. M. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.174 · Cited by 446
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM
Song, H., Hollstein, M., & Xu, Y. (2007) · Nature Cell Biology · doi:10.1038/ncb1571 · Cited by 439
Rouault, J.-P., Falette, N., Guéhenneux, F., Guillot, C., Rimokh, R., Wang, Q., Berthet, C., Moyret-Lalle, C., Savatier, P., Pain, B., et al. (1996) · Nature Genetics · doi:10.1038/ng1296-482 · Cited by 434
Bullock, A. N., Henckel, J., & Fersht, A. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203434 · Cited by 434
Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo
Luo, J., Li, M., Tang, Y., Laszkowska, M., Roeder, R. G., & Gu, W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308762101 · Cited by 422
HIV-1 Tat transcriptional activity is regulated by acetylation
Kiernan, R. E. (1999) · The EMBO Journal · doi:10.1093/emboj/18.21.6106 · Cited by 416
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs
Joerger, A. C., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607286103 · Cited by 353
p53 Acetylation: Regulation and Consequences
Reed, S., & Quelle, D. (2014) · Cancers · doi:10.3390/cancers7010030 · Cited by 332
Structural Mechanism of the Bromodomain of the Coactivator CBP in p53 Transcriptional Activation
Mujtaba, S., He, Y., Zeng, L., Yan, S., Plotnikova, O., Sachchidanand, Sanchez, R., Zeleznik-Le, N. J., Ronai, Z., & Zhou, M.-M. (2004) · Molecular Cell · doi:10.1016/s1097-2765(03)00528-8 · Cited by 319
Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate
Knights, C. D., Catania, J., Giovanni, S. D., Muratoglu, S., Perez, R., Swartzbeck, A., Quong, A. A., Zhang, X., Beerman, T., Pestell, R. G., et al. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200512059 · Cited by 287
Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
Hay, D. A., Fedorov, O., Martin, S., Singleton, D. C., Tallant, C., Wells, C., Picaud, S., Philpott, M., Monteiro, O. P., Rogers, C. M., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja412434f · Cited by 277
An interconnected hierarchical model of cell death regulation by the BCL-2 family
Chen, H.-C., Kanai, M., Inoue-Yamauchi, A., Tu, H.-C., Huang, Y., Ren, D., Kim, H., Takeda, S., Reyna, D. E., Chan, P. M., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3236 · Cited by 249
Waarts, M. R., Stonestrom, A. J., Park, Y. C., & Levine, R. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154943 · Cited by 230
Deconstructing networks of p53-mediated tumor suppression in vivo
Kaiser, A. M., & Attardi, L. D. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.171 · Cited by 227
Prion-like aggregation of mutant p53 in cancer
Silva, J. L., Gallo, C. V. D. M., Costa, D. C. F., & Rangel, L. P. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.04.001 · Cited by 201
Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode
Wang, D., Kon, N., Lasso, G., Jiang, L., Leng, W., Zhu, W.-G., Qin, J., Honig, B., & Gu, W. (2016) · Nature · doi:10.1038/nature19759 · Cited by 199
Scolnick, D. M., Chehab, N. H., Stavridi, E. S., Lien, M. C., Caruso, L. C., Morán, E., Berger, S. L., & Halazonetis, T. D. (1997) · PubMed · Cited by 184
MOZ increases p53 acetylation and premature senescence through its complex formation with PML
Rokudai, S., Laptenko, O., Arnal, S. M., Taya, Y., Kitabayashi, I., & Prives, C. L. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300490110 · Cited by 183
Analysis of human acetylation stoichiometry defines mechanistic constraints on protein regulation
Hansen, B. K., Gupta, R., Baldus, L., Lyon, D., Narita, T., Lammers, M., Choudhary, C., & Weinert, B. T. (2019) · Nature Communications · doi:10.1038/s41467-019-09024-0 · Cited by 183
The C terminus of p53 binds the N-terminal domain of MDM2
Poyurovsky, M. V., Katz, C., Laptenko, O., Beckerman, R., Lokshin, M., Ahn, J., Byeon, I. L., Gabizon, R., Mattia, M., Zupnick, A., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1872 · Cited by 172
The many lives of KATs — detectors, integrators and modulators of the cellular environment
Sheikh, B. N., & Akhtar, A. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0072-4 · Cited by 172
The transcription factor p53: Not a repressor, solely an activator.
Fischer, M., Steiner, L., & Engeland, K. (2014) · Cell Cycle · doi:10.4161/15384101.2014.949083 · Cited by 153
Palanikumar, L., Karpauskaite, L., Al-Sayegh, M., Chehade, I., Alam, M., Hassan, S., Maity, D., Ali, L., Kalmouni, M., Hunashal, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23985-1 · Cited by 132
Chao, C., Wu, Z., Mazur, S. J., Borges, H. L., Rossi, M., Lin, T., Wang, J. Y. J., Anderson, C. W., Appella, E., & Xu, Y. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00062-06 · Cited by 130
Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer
Silva, J. L., Cino, E. A., Soares, I. N., Ferreira, V. F., & de Oliveira, G. A. P. (2017) · Accounts of Chemical Research · doi:10.1021/acs.accounts.7b00473 · Cited by 127
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
Nishikawa, S., & Iwakuma, T. (2023) · Cancers · doi:10.3390/cancers15020429 · Cited by 115
Targeted protein acetylation in cells using heterobifunctional molecules
Wang, W. W., Chen, L.-Y., Wozniak, J. M., Jadhav, A. M., Anderson, H., Malone, T. E., & Parker, C. G. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c07850 · Cited by 114
Self-citationMolecular glues and bifunctional compounds: Therapeutic modalities based on induced proximity
Schreiber, S. L. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.05.004 · Cited by 112
p53, a novel regulator of lipid metabolism pathways
Goldstein, I., Ezra, O., Rivlin, N., Molchadsky, A., Madar, S., Goldfinger, N., & Rotter, V. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.022 · Cited by 102
A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
Guiley, K. Z., & Shokat, K. M. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0381 · Cited by 102
Distinct pattern of p53 phosphorylation in human tumors
Minamoto, T., Buschmann, T., Habelhah, H., Matusevich, E., Tahara, H., Børresen‐Dale, A., Harris, C. C., Sidransky, D., & Ronai, Z. A. (2001) · Oncogene · doi:10.1038/sj.onc.1204458 · Cited by 100 · cited 1×
“85,86 However, a precise understanding of specific acetylation events, as well as the potential roles of p300/CBP and PCAF/GCN5, on the transcriptional activity of common cancer associated p53 mutants is not firmly established.”
Love, I. M., Šekaric, P., Shi, D., Grossman, S. R., & Androphy, E. J. (2012) · Cell Cycle · doi:10.4161/cc.20864 · Cited by 98
Discovery of a PCAF Bromodomain Chemical Probe
Moustakim, M., Clark, P. G. K., Trulli, L., de Arriba, A. L. F., Ehebauer, M. T., Chaikuad, A., Murphy, E. J., Méndez, J., Daniels, D. L., Hou, C.-F. D., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201610816 · Cited by 94
Pharmacological reactivation of p53 in the era of precision anticancer medicine
Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 93 · cited 1×
“116 Our observation that targeted acetylation of multiple frequently occurring p53 mutants results in increased stability and transcriptional activity with no observable increases in aggregation provides compelling evidence of an alternative strategy.”
Determining Protein Half-Lives
Zhou, P. (2004) · Humana Press eBooks · doi:10.1385/1-59259-816-1:067 · Cited by 86
Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm
Bauer, M. R., Krämer, A., Settanni, G., Jones, R. N., Ni, X., Khan Tareque, R., Fersht, A. R., Spencer, J., & Joerger, A. C. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.9b00748 · Cited by 84
Identification of SCN3B as a novel p53-inducible proapoptotic gene
Adachi, K., Toyota, M., Sasaki, Y., Yamashita, T., Ishida, S., Ohe-Toyota, M., Maruyama, R., Hinoda, Y., Saito, T., Imai, K., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1208067 · Cited by 82
Eldar, A., Rozenberg, H., Diskin-Posner, Y., Rohs, R., & Shakked, Z. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt630 · Cited by 72
Masud, A. J., Kastaniotis, A. J., Rahman, M., Autio, K. J., & Hiltunen, J. K. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118540 · Cited by 71
Wang, K., Escobar, M., Li, J., Mahata, B., Goell, J., Shah, S. T., Cluck, M., & Hilton, I. B. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac582 · Cited by 71
hCLCA2 Is a p53-Inducible Inhibitor of Breast Cancer Cell Proliferation
Walia, V., Ding, M., Kumar, S., Nie, D., Premkumar, L. S., & Elble, R. C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4101 · Cited by 67
Promoter-specific p53-dependent histone acetylation following DNA damage
Kaeser, M. D., & Iggo, R. D. (2004) · Oncogene · doi:10.1038/sj.onc.1207536 · Cited by 65 · cited 1×
“Notably, no significant increase of H3Ac at CDKN1A promoters 82 (Figure 3b) is observed after treatment, suggesting that p300/CBP recruitment to p53 does not lead to indirect acetylation of proximal histones.”
Acetylation targeting chimera enables acetylation of the tumor suppressor p53
Kabir, M., Sun, N., Hu, X., Martin, T. C., Yi, J., Zhong, Y., Xiong, Y., Kaniskan, H. Ü., Gu, W., Parsons, R., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c04640 · Cited by 65
Deciphering the acetylation code of p53 in transcription regulation and tumor suppression
Xia, Z., Kon, N., Gu, A. P., Tavana, O., & Gu, W. (2022) · Oncogene · doi:10.1038/s41388-022-02331-9 · Cited by 60
The transcriptional co-activator PCAF regulates cdk2 activity
Mateo, F., Vidal-Laliena, M., Canela, N., Zecchin, A., Martínez-Balbás, M., Agell, N., Giacca, M., Pujol, M. J., & Bachs, O. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp777 · Cited by 55
FGFR3 has tumor suppressor properties in cells with epithelial phenotype
Lafitte, M., Moranvillier, I., Garcia, S., Peuchant, E., Iovanna, J., Rousseau, B., Dubus, P. R., Guyonnet‐Dupérat, V., Belleannée, G., Ramos, J., et al. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-83 · Cited by 53
Sundar, D., Yu, Y., Katiyar, S. P., Putri, J. F., Dhanjal, J. K., Wang, J., Sari, A. N., Kolettas, E., Kaul, S. C., & Wadhwa, R. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1099-x · Cited by 51
Möllerström, E., Kovács, A., Lövgren, K., Nemes, S., Delle, U., Danielsson, A., Parris, T. Z., Brennan, D. J., Jirström, K., Karlsson, P., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-296 · Cited by 46
PLTP is a p53 target gene with roles in cancer growth suppression and ferroptosis
Gnanapradeepan, K., Indeglia, A., Stieg, D. C., Clarke, N. L., Shao, C., Dougherty, J. F., Murali, N., & Murphy, M. E. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102637 · Cited by 44
Non-histone protein acetylation by the evolutionarily conserved GCN5 and PCAF acetyltransferases
Downey, M. (2020) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2020.194608 · Cited by 42
Identification of lipidomic profiles associated with drug-resistant prostate cancer cells
Ingram, L. M., Finnerty, M. C., Mansoura, M., Chou, C.-W., & Cummings, B. S. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01437-5 · Cited by 42
Liu, T., Wang, X., Hu, W., Fang, Z., Jin, Y., Fang, X., & Miao, Q. R. (2019) · Neoplasia · doi:10.1016/j.neo.2019.03.011 · Cited by 41
Zhang, Y.-Q., Liang, Y.-K., Wu, Y., Chen, M., Chen, W.-L., Li, R., Zeng, Y.-Z., Huang, W.-H., Wu, J.-D., Zeng, D., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03735-3 · Cited by 41
Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation
Kong, L. R., Ong, R., Tan, T. Z., Salleh, N. A. B. M., Thangavelu, M. T., Chan, J. V., Koh, L. Y. J., Periyasamy, G., Lau, J. A., Le, T. B. U., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15608-y · Cited by 38
Hzf, a p53-Responsive Gene, Regulates Maintenance of the G2 Phase Checkpoint Induced by DNA Damage
Sugimoto, M., Gromley, A., & Sherr, C. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.26.2.502-512.2006 · Cited by 35
Gu, J. H., Zhang, L., Swisher, S. G., Liu, J., Roth, J. A., & Fang, B. (2003) · Oncogene · doi:10.1038/sj.onc.1207239 · Cited by 33
Chaudhry, S. R., Lopes, J. L., Levin, N. K., Kalpage, H. A., & Tainsky, M. A. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00442-y · Cited by 32
PCAF-mediated Akt1 acetylation enhances the proliferation of human glioblastoma cells
Zhang, S., Sun, G., Wang, Z., Wan, Y., Guo, J. X., & Shi, L. (2014) · Tumor Biology · doi:10.1007/s13277-014-2522-8 · Cited by 30
PIG3 promotes NSCLC cell mitotic progression and is associated with poor prognosis of NSCLC patients
Li, M., Li, S., Liu, B., Gu, M.-M., Zou, S., Xiao, B.-B., Yu, L., Ding, W., Zhou, P., Zhou, J., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0508-2 · Cited by 30
The role of acetylation sites in the regulation of p53 activity
Wang, Y., Chen, Y., Chen, Q., Zhang, X., Wang, H., Wang, Z., Wang, J., & Tian, C. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-05141-7 · Cited by 29
N-acetylcysteine potentiates doxorubicin-induced ATM and p53 activation in ovarian cancer cells
Brum, G., Carbone, T., Still, E., Correia, V., Szulak, K., Calianese, D. C., Best, C., Cammarata, G. M., Higgins, K., Ji, F., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1680 · Cited by 27
Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53
Warnock, L. J., Raines, S. A., & Milner, J. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.12.18141 · Cited by 26 · cited 1×
“85,86 However, a precise understanding of specific acetylation events, as well as the potential roles of p300/CBP and PCAF/GCN5, on the transcriptional activity of common cancer associated p53 mutants is not firmly established.”
Zhao, K., Wang, D., Zhao, X., Wang, C., Gao, Y., Liu, K., Wang, F., Wu, X., Wang, X., Sun, L., et al. (2020) · EMBO Reports · doi:10.15252/embr.201949269 · Cited by 25
Wu, Y. F., Liu, X., Wang, X.-J., Zhang, Y., Liang, X., & Cao, E. (2008) · Pathology & Oncology Research · doi:10.1007/s12253-008-9138-5 · Cited by 22
Lysines in the tetramerization domain of p53 selectively modulate G1 arrest
Beckerman, R., Yoh, K. E., Mattia-Sansobrino, M., Zupnick, A., Laptenko, O., Karni-Schmidt, O., Ahn, J., Byeon, I. L., Keezer, S. M., & Prives, C. L. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1170270 · Cited by 20
The “readers” of unacetylated p53 represent a new class of acidic domain proteins
Wang, D., Kon, N., Tavana, O., & Gu, W. (2017) · Nucleus · doi:10.1080/19491034.2017.1313939 · Cited by 19
Balasundaram, A., & Doss, C. G. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415499 · Cited by 18
da Paz, M. M., Ferretti, G. D. S., Martins-Dinis, M. M. D. C., Ferreira, B. I. S., Faier-Pereira, A., Barnoud, T., Moreira, O. C., Silva, J. L., Cordeiro, Y., & Rangel, L. P. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1165132 · Cited by 18
Secchiero, P., Rimondi, E., di Iasio, M. G., Voltan, R., Gonelli, A., & Zauli, G. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22910 · Cited by 16
MAST4 controls cell cycle in spermatogonial stem cells
Lee, S., Kim, K., Lee, D., Kim, P., Park, J., Kim, S., & Jung, H.-S. (2023) · Cell Proliferation · doi:10.1111/cpr.13390 · Cited by 15
Identification of New p53 Acetylation Sites in COS-1 Cells
Joubel, A., Chalkley, R. J., Medzihradszky, K. F., Hondermarck, H., & Burlingame, A. L. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800487-mcp200 · Cited by 14
High-efficiency knock-in of degradable tags (dTAG) at endogenous loci in cell lines
Mehta, S., Buyanbat, A., Orkin, S. H., & Nabet, B. (2022) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2022.08.045 · Cited by 14
Xu, D., Qian, W., Yang, Z., Zhang, Z., Sun, P., Wan, Q., Yin, Y., Hu, Y., Gong, L., Zhang, B., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107003 · Cited by 14
The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability
Abad, E., Sandoz, J., Romero, G., Zadra, I., Urgel-Solas, J., Borredat, P., Kourtis, S., Ortet, L., Martínez, C. M., Weghorn, D., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03045-4 · Cited by 14
Insights into Allosteric Mechanisms of the Lung-Enriched p53 Mutants V157F and R158L
Lei, J., Li, X., Cai, M., Guo, T., Lin, D., Deng, X., & Li, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710100 · Cited by 11
SAC3D1 activates Wnt/β‑catenin signalling in hepatocellular carcinoma
Wang, H., & Shi, X. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12833 · Cited by 10
Hämäläinen, L., Bart, G., Takabe, P., Rauhala, L., Deen, A. J., Pasonen‐Seppänen, S., Kärkkäinen, E., Kärnä, R., Kumlin, T., Tammi, M., et al. (2021) · Histochemistry and Cell Biology · doi:10.1007/s00418-021-01962-5 · Cited by 8
A heterobifunctional molecule system for targeted protein acetylation in cells
Chen, L., Wang, W., Wozniak, J. M., & Parker, C. G. (2022) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2022.08.014 · Cited by 8
Self-citationDRAXIN as a Novel Diagnostic Marker to Predict the Poor Prognosis of Glioma Patients
Jia, Y., Liu, Z., Cheng, X., Liu, R., Li, P., Kong, D., Liang, W., Liu, B., Wang, H., Bu, X., et al. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02054-2 · Cited by 5
(1995) · PubMed
Research works printed but not linked: 3
- Waldman T., 1995, Cancer Res., 55, 5187
- Scolnick D. M., 1997, Cancer Res., 57, 3693
- Mehta S., 2023, Methods in Enzymology, 1
Cited by
Induced proximity-based therapeutic modalities
King, E. A., Meyers, M., & Nomura, D. K. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01316-z · Cited by 72
“262,263) (Fig.”
Acetylation: a new target for protein degradation in cancer
Crawford, C. E. W., & Burslem, G. M. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2025.01.013 · Cited by 20
A bivalent molecular glue linking lysine acetyltransferases to oncogene-induced cell death
Nix, M. N., Gourisankar, S. P., Bowman, K., Nettles, S. A., Yang, H. H., Dwyer, B. G., Sarott, R. C., Abuzaid, H. Z., Martinez, M. M., Phillips, N. A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.06.037 · Cited by 19
Self-citationTargeted Protein Acetylation Through Chemically Induced Proximity
Wang, W., Roy, S. J. S., & Parker, C. G. (2025) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5c00326 · Cited by 14
Self-citationHarnessing the TAF1 Acetyltransferase for Targeted Acetylation of the Tumor Suppressor p53
Kabir, M., Hu, X., Martin, T. C., Pokushalov, D., Kim, Y. J., Chen, Y., Zhong, Y., Wu, Q. D., Chipuk, J. E., Shi, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202413377 · Cited by 13
Metadata
- Authors
- Chen, L.-Y., Singha Roy, S. J., Jadhav, A. M., Wang, W. W., Chen, P.-H., Bishop, T., Erb, M. A., & Parker, C. G.
- Affiliations
- Department of Chemistry
- Scripps Research Institute (US)
- Corresponding author
- Parker, Christopher G.
- ORCID
- Venue
- ACS Chemical Biology
- Publisher
- American Chemical Society (ACS)
- Published
- 2024-09-09
- Volume
- 19
- Issue
- 9
- Pages
- 1918-1929
- ISSN
- 1554-8929 (ISSN-L)
- 1554-8937
- PMC
- PMC11421428
- OpenAlex
- W4402349055
- Cited by
- 18
- References
- 117
- Citations by year
- 2026: 11 · 2025: 6 · 2024: 1
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- ACS Chemical Biology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R01CA280720)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Keywords
- p53 acetylation, CBP/p300, post-translational modification, p53 stabilization, transcriptional activity, cancer cells, acetyltransferase
- MeSH terms
- p300-CBP-Associated Factor, Acetylation, Humans, Protein Processing, Post-Translational, Tumor Suppressor Protein p53, Cell Line, Tumor, p300-CBP Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.